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Platelet lysate enhances synovial fluid multipotential stromal cells functions, 
implications for therapeutic use. 
Ala Altaie, Thomas G Baboolal, Owen Wall,
 
Elena Jones, Dennis McGonagle.   
Leeds Institute of Rheumatic and Musculoskeletal Medicine 
Objective: Whilst intra-articular injection of platelet products is increasingly being used for 
joint regenerative approaches, there is limited data on their biological effects on joint resident 
multipotential stromal cells (MSCs) which are directly exposed to the effects of these 
therapeutic strategies. Therefore, this study investigated the effect of platelet lysate (PL) on 
synovial fluid-derived MSCs (SF-MSCs), which in vivo have direct access to sites of cartilage 
injury.  
Methods: SF-MSCs were obtained during knee arthroscopic procedures (N=7). Colony 
forming unit–fibroblastic (CFU-F), flow-cytometric phenotyping, CFSE based 
immunomodulation for T cells and trilineage differentiation assays were performed using PL 
and compared to standard conditions. 
Results:  PL enhanced SF-MSCs proliferation as CFU-F colonies were 1.4-fold larger and 
growing cultures had shorter population doubling-times. PL-MSCs and FCS-MSCs had the 
same immunophenotype and similar immunomodulation activities. In chondrogenic and 
osteogenic differentiation assays, MSCs grown in PL or “PL-MSCs” produced 10 % more 
sulphated-glycosaminoglycan (sGAG) and 45 % less Ca++ compared to FCS-MSCs, 
respectively. Replacing chondrogenic media TGF-E with 20 % or 50 % PL further increased 
sGAG production of PL-MSCs by 69 % and 95 % respectively, compared to complete 
chondrogenic media. Also, DMEM-(high-glucose) plus 50 % PL induced more chondrogenesis 
compared to DMEM-(high-glucose) plus 10 % FCS and was comparable to complete 
chondrogenic media.  
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Conclusion: This is the first study to assess SF-MSCs responses to PL and provides biological 
support that PL may be capable of modulating multiple functional aspects of joint resident 
MSCs which have direct access to injured cartilage.    
Key words: Synovial fluid multipotential stromal cells, platelet lysate and chondrogenesis.  
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Introduction: 
 
Osteoarthritis (OA) is the most common musculoskeletal disease that affects an increasing 
proportion of the population and is a major cause of global healthcare expenditure [1]. The OA 
process can start in multiple locations within the joint including the cartilage, bone, ligaments, 
synovium and meniscus, with eventual whole joint failure [2]. To date, there are limited 
therapeutic options for the treatment of joint dysfunction in OA. For early OA emanating in 
cartilage or “chondrogenic” OA, symptomatic treatments with analgesics, non-steroid 
medications, steroid injection and physical therapy, rather than regenerative approaches are 
invariably offered  [3, 4]. In more advanced disease, total knee replacement is generally 
considered in patients over 65 years and more than 160,000 of these are carried out annually 
in the UK alone (according to National Joint Registry, 2017). However, in younger patients 
with small sized chondral lesions, regenerative therapies including microfracture and 
autologous chondrocyte implantation (ACI) may be used. Although these approaches are 
associated with good short term pain relief, they mostly lead to formation of fibrocartilaginous 
tissue which is not capable of withstanding mechanical stresses over time [5-7].  
There is an urgent need for novel regenerative treatment options for isolated articular cartilage 
defects before they lead to advanced cartilage loss. One experimental strategy is the use of 
bone marrow-derived MSCs (BM-MSCs) [8, 9], or adipose tissue-derived MSCs (AT-MSC) 
[10, 11], with pre-clinical and clinical results showed promising results.  However, due to the 
expense and time-consuming nature of these procedures, as they require clinical grade facilities 
and times to expand the cells, there is an increasing interest in harnessing the power of 
endogenous joint resident MSCs in conjunction with scaffolds or growth factors or a 
combination as part of a one stage procedure.     
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One potential source of endogenous MSCs that could play a role in OA joint repair are synovial 
fluid-derived MSCs (SF-MSCs) that are present in OA, rheumatoid arthritis (RA) and non-
arthritic joint fluid [12].  Elevation in SF-MSC numbers has been reported in early OA, and 
following meniscal injury, suggesting their potential role in physiological joint repair [13, 14]. 
Furthermore, SF-MSCs are easy to isolate by aspiration and they are thought to be derived 
from the adjacent synovium, which is a tissue rich in MSCs with strong chondrogenic potential 
[15, 16]. Finally, animal model studies showed that synovial origin MSCs facilitated cartilage 
repair following injection directly to the defect area with or without scaffold [17, 18].   Since 
both the topography and high chondrogenic potential of SF-MSCs indicate their potential role 
in endogenous joint repair, the question arises as to whether this process could be exploited or 
further enhanced.    
 
Platelet Lysate (PL) is a biological platelet derivative rich in growth factors and cytokines that 
encourage tissue repair, which is driven by a multitude of growth factors including basic 
fibroblast-derived growth factor (bFGF), transforming growth factor beta (TGF-ȕ, platelet 
derived growth factor-AA (PDGF-AA), PDGF-AB, PDGF-BB,  [19, 20]. Increasingly, PL is 
being injected directly into OA knee joints with some encouraging results [21] but the 
mechanisms of its action remain unknown. In 2005, Doucet proposed the use of PL as a 
substitute to FCS for MSC expansion intended for cellular therapy [22]. Subsequent studies 
have shown the capacity of PL to promote cell proliferation while maintaining 
immunophenotype and trilineage differentiation of BM-MSCs, AT-MSCs and umbilical cord 
blood MSCs [20, 23-26]. The potential interactions between PL and SF-MSCs have not thus 
far been explored, but could be key towards enhancing the endogenous MSC repair responses. 
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The aim of this study was therefore to evaluate the impact of PL on SF-MSCs 
immunophenotype, proliferation, immunomodulation, and trilineage differentiation in 
comparison to FCS containing standard expansion media, with a particular focus of the 
capacity of PL to act as chondrogenic inducer. We studied commercial PL ((Stemulate) from 
Cook Regentec) as it has a more consistent growth factor content as it is produced in large 
batches to avoid lot to lot variation and is available off the shelf in large quantities. 
 
Patients and Methods: 
Isolation and culture of SF-MSCs 
Approval for the study was obtained from the national research ethics committee (Rec 
reference:14/YH/0087). Samples were collected after informed written consent from all study 
participants who were undergoing elective knee diagnostic or therapeutic arthroscopy. No 
effusion was present at time of arthroscopy and patients with inflamed synovium were not 
included as inflammation might have an impact on chondrogenesis [15]. To ensure collection 
of all SF-MSCs, SF was collected after an initial injection of saline (up to 50ml) (N=7 patients). 
The aspirated fluid was centrifuged at 500rcf for 5 minutes and cells were re-suspended in 
10ml DMEM media (with no FCS). For expansion, 2ml of cell suspension were cultured in 
PL-media containing DMEM (Gibco Paisley-UK) supplemented with 5% PL-fibrinogen 
depleted (Stemulate, Cook Regentec-US) (referred to as PL-MSCs) or standard FCS-media 
(StemMACS media, Miltenyi Biotec-UK) (referred to as FCS-MSCs); each containing 100 
units/ml penicillin, 100mg/ml streptomycin (all from Gibco).  Cells were incubated in a 
humidified atmosphere at 37qC and 5 % CO2, with a full media change after 48 hours, followed 
by media changes twice weekly. Once the cells reached 80 % confluence, the adherent cells 
were harvested with 0.25 % trypsin/1 mM ethylenediaminetetraacetic acid (EDTA) solution 
(Sigma-Aldrich, Dorset, UK) and passaged at a seeding density of 5–7 x 103 cells/cm2. Donor-
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matched cultures were used in all experiments when they reached passage 3. SF-MSCs 
doubling time was calculated from the number of population doublings up to passage 0 as 
previously described [27]. According to the following formula: days in culture till the end of 
passage 0/population doubling number up to passage 0. The latter (population doubling 
number) was calculated as = log2 (N total cell count at p0/ Total CFU-F number). 
Characterisation of the surface marker expression 
The following antibodies were used to compare immunophenotype of PL- and FCS- expanded 
SF-MSCs: CD90-PE-Cy7, CD45-PE-Cy7 and CD19-PE (BD Biosciences Pharmigen-UK), 
CD105-PE (AbD Serotec-UK), PE-CD73, CD34-APC and CD14-FITC (Miltenyi biotec-UK), 
with appropriate isotype controls. DAPI was used to gate out dead cells. Samples were acquired 
using a three-laser flow cytometer, LSRII (BD Biosciences) and analysed by FacsDiva version 
8.   
 
Colony-forming unit–fibroblast (CFU-F) assay: 
Freshly obtained SF cells were plated in duplicate 60 mm diameter petri dishes (Greiner bio-
UK) either with FCS- or PL-media. Cells were incubated in a humidified atmosphere at 37qC 
and 5 % CO2, with a full media change after 48 hours, followed by half media changes three 
times a week. Colonies were stained with 1 % methylene blue after 2 weeks of culture for 
counting and measuring colony size using ImageJ version 2.0.0.  
To ensure that any potential differences in colony counts were due to SF-MSCs proliferation 
in the different media rather than differential adhesion, SF-MSCs adhesion to the plastic under 
both conditions was assessed. After the initial seeding and attachment phase, a full media 
change was performed after 48 hours and cells were washed with Phosphate Buffer Saline 
(PBS). PL-media was added to the cells which were originally plated with FCS-media, and 
vice versa. After 14 days, colonies were fixed and stained with 1 % methylene blue. 
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Standard trilineage differentiation assays: 
Trilineage differentiation potential of PL-MSCs was initially examined in comparison to FCS-
MSCs. For chondrogenic differentiation, donor-matched  replicate cultures of FCS-MSCs and 
PL-MSCs (5 replicates of 2.5x105 cells each) were placed in screw-capped Eppendorf tubes 
(BDH Chemicals-UK) in 0.5 ml of complete chondrogenic media consisting of DMEM (high 
glucose), 50 Pg/ml Ascorbic-2-phosphate (As2P), 100 Pg/ml Sodium Pyruvate, 40 Pg/ml 
Proline, 1.25 mg/ml bovine serum albumin, 1:100 of mixture of recombinant human insulin, 
human transferrin, and sodium selenite (ITS+), 10 nM dexamethasone (DEX) and 10 ng/ml 
transforming growth factor-beta (3) (TGF-ȕ), all from Sigma [14]. Half media changes were 
performed 3 times a week. After 3 weeks, sGAG production was visualized on 5 Pm frozen 
sections stained with 1 % toluidine blue (Sigma). Production of sGAG was further quantified 
using an Alcian blue binding assay (Immunodiagnostic Systems, Boldon, UK) following 
digestion in 100 Pl of papain solution [14]. For osteogenic differentiation, 5 replicates of donor-
matched FCS-MSCs and PL-MSCs (104 cell/well) were seeded in 12 well tissue culture plates 
with freshly prepared complete osteogenic media (DMEM, 10 % FCS, 100 PM As2P, 10 mM 
E glycerophosphate and 100 nM DEX, all from Sigma) [28]. Media was changed twice a week 
and after 21 days, cells were washed with PBS, fixed and stained with 1 % Alizarin red 
(Sigma). For calcium quantification, cells were incubated in 0.5 N HCl for 5 minutes and gently 
scraped off the surface before agitating for 4 hours at 4oC. Quantification was performed using 
the Ca++ liquid assay according to manufactures instructions (Sentinel Diagnostics-UK) [14]. 
For adipogenesis, 24 well plates were seeded with 5 replicate cultures of donor matched FCS-
MSCs and PL-MSCs (5x104 cells/well) in freshly prepared complete adipogenic media; 
DMEM (low glucose) supplemented with 10 % FCS, 10 % horse serum, 0.5 mM 
isobutylmethylxantine, 60 PM indomethacine and 0.5 mM hydrocortisone (all from sigma) 
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[14]. Media was changed twice a week and after 3 weeks quantitative analysis was performed 
by initially staining cells with DAPI (8 Pg/ml) and measuring fluorescence from excitation and 
emission at 355/460 nm. Cells were further stained with Nile red (1 Pg/ml) and fluorescence 
measured from excitation and emission at 485/535 nm using Berthold plate reader [29]. The 
ratio of Nile red to DAPI was then calculated [29]. For Oil Red staining, cells were fixed in 10 
% (v/v) formalin (Biostain Ready Reagents, Manchester, UK) and stained with oil red solution 
0.5 % oil red (w/v) (Sigma) in isopropanol, as previously described [29].  
 
PL as a trilineage differentiation inducer: 
To investigate whether PL can act as chondrogenic inducer, different chondrogenic media were 
prepared as follows. First, to examine if PL can replace TGF-E3, basal chondrogenic media 
was prepared which contained DMEM (high glucose), 50 Pg/ml As2P, 100 Pg/ml Sodium 
Pyruvate, 40 Pg/ml Proline, 1.25 mg/ml bovine serum albumin, 1:100 of mixture of 
recombinant human insulin, human transferrin, and ITS+ and 10 nM DEX). Instead of TGF-
E3, this basal media was supplemented with 20 % PL and 50 % PL (referred to as basal 
chondro-20 % PL and -50 % PL respectively). Secondly, to investigate if PL alone can induce 
chondrogenesis without addition of any other inducer molecules present in basal chondrogenic 
media, DMEM (high glucose) media was supplemented with 50 % PL alone (referred to as 
DMEM, 50 % PL). DMEM with 10 % FCS and no inducers was used a negative control, 
chondrogenesis was performed as described earlier. In osteogenic and adipogenic complete 
media, 10 % FCS was replaced with 10 % PL (referred to as Osteo-PL and Adipo-PL), assays 
were performed as described earlier.  
 
Immunomodulation assay: 
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Peripheral blood mononuclear cells (PBMCs) were obtained using Lymphoprep reagent (Axis-
Shield, Oslo, Norway) from heathy donors, with informed consent. Prior to co-culture, donor-
matched PL-MSCs or FCS-MSCs were irradiated (30 Gy) to prevent further proliferation of 
MSCs. PBMCs were stained with Carboxyfluorescein succinimidyl ester (CFSE, Invitrogen-
UK) according to the manufacturer’s protocol. Co-cultures were performed in 24 well plates 
with following ratios of PBMCs to SF-MSCs 1:1, 2:1, 5:1 and 10:1. Wells containing no MSCs 
were used as positive controls. Human CD3/CD28 Dynabeads (Invitrogen-UK) were used to 
stimulate T-Lymphocyte proliferation [30]. Non-stimulated PBMCs in the absence of SF-
MSCs were used as negative controls. Glutamax™ RPMI 1640 media (Invitrogen-UK) 
supplemented with 10 % FCS was added to all wells. Flow cytometry analysis was performed 
five days after stimulation. CD4+ T cells were gated based on viability (using 7-AAD), 
followed by gating on the CD90-CD45+ population (to exclude any MSCs), and finally, on the 
CD14-CD4+ population. T-lymphocyte proliferation was analysed using ModFit software 
version 5.0.9 (Verity Software House, Topsham, ME. USA). T-lymphocyte proliferation was 
calculated using a proliferation index, the ratio of the starting population plus daughter cells 
divided by the starting population cell count [31].  
Statistics: 
All statistical analyses were carried out using GraphPad Prism software (GraphPad software). 
Wilcoxon matched-pairs signed rank test was used to compare proliferation and standard 
trilineage differentiation of PL-MSCs to FCS-MSCs. Two-Way ANOVA–Bonferroni's 
multiple comparisons tests for group analysis were performed to compare immunosuppression 
of SF-MSCs at different co-culture ratios and immunosuppression of PL-MSCs to FCS-MSCs, 
trilineage differentiation of PL-MSCs and FCS-MSCs with different induction media.  
 
Results: 
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PL maintains the SF-MSCs phenotype  
Flow cytometric analysis showed FCS-MSCs lacked expression of CD14, CD19, CD34 and 
CD45 cell surface markers and positively expressed CD73 (95.6 ± 3.0 %), CD90 (96.33 ± 1.0 
%) and CD105 (92 ± 2.8 %) (Figure 1). Similarly, PL-MSCs lacked expression of CD14, 
CD19, CD34 and expressed positive for CD73 (98.5 ± 1.1 %), CD90 (97.6 ± 2.8 %) and CD105 
(89.6 ± 10 %).  Thus, the immunophenotype of PL-MSCs was consistent with International 
Society for Cell Therapy (ISCT) basic requirements for expanded MSCs as they were 
compared to donor-matched FCS-MSCs. 
 
PL enhancement of SF-MSCs proliferation  
Using the CFU-F assay, comparisons were made to investigate the impact of PL on SF-MSCs 
proliferation compared to FCS containing media. PL significantly increased SF-MSCs 
proliferation, with 1.4-fold change compared to FCS (p<0.05, N=7, Figure 2A-C). In 
agreement with the CFU-F results, PL significantly shortened the doubling time of SF-MSC 
cultures as compared to FCS expanded cells at the end of passage 0 (p<0.05, N=7, Figure 2D). 
There was no significant difference in colony numbers of SF-MSCs plated with PL or FCS 
(Figure 2E). To confirm that PL had no impact on SF-MSCs adhesion to the plastic, while 
affecting their proliferation, colony numbers were compared in different attachment conditions. 
Results showed that cells plated with either PL in the first 48 hours (PL48) or with FCS in the 
first 48 hours (FCS48), had no significant difference in the colony numbers (Figure 2F). In 
conclusion PL, significantly increased proliferation of SF-MSCs and had no significant impact 
on their adhesion to plastic.  
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Comparisons of PL-MSCs and FCS-MSCs trilineage differentiation  
To assess the differentiation potential of PL-MSCs towards osteoblasts, adipocytes and 
chondrocytes compared to FCS-MSCs, MSC differentiation assays were performed using 
donor matched cultures grown in PL or under standard conditions. PL-MSCs showed 
significant potential to undergo chondrogenesis in complete chondrogenic media when 
compared to FCS-MSCs. After 21 days in culture with complete chondrogenic media, PL-
MSCs and FCS-MSCs pellets were obtained, and positively stained for glycosaminoglycans 
(Figure 3A).  The sGAG production quantified after pellet digestion revealed that PL-MSCs 
produced on average 10 % more sGAG compared to FCS-MSCs (p<0.05, N=5, Figure 3A). 
However, PL-MSCs cultured with complete osteogenic media for 21 days deposited on average 
45 % less Ca++ compared to FCS-MSCs (p<0.05, N=5, Figure 3B). Alizarin red staining of PL-
MSCs confirmed less Ca++ deposition compared to FCS-MSCs (Figure 3B). Finally, using 
complete adipogenic media, PL-MSCs showed no difference in the accumulated lipid vacuoles 
and the Nile red/DAPI ratio was comparable to FCS-MSCs (Figure 3C). 
 
PL has the potential to act as chondrogenic inducer  
PL was also evaluated as a chondrogenic inducer by either replacing TGF-E3 in the complete 
media or as chondrogenic inducer alone. These data showed that replacing 10 ng TGF-Ewith 
20 % or 50 % PL in the basal chondrogenic media led to 69 % and 95 % increases in sGAG 
production by PL-MSCs, respectively, (p൑0.0001 N=5, Figure 4A). Additionally, 20 % and 
50 % of PL increased the sGAG produced FCS-MSCs 50 % and 84 % (p<0.05, N=5, Figure 
4A). Furthermore, using high glucose DMEM with 50 % PL alone induced chondrogenesis in 
both cultures compared to the negative control (DMEM high glucose with 10 % FCS) with 
sGAG production comparable to that of complete chondrogenic media, (p<0.0001, N=5, Figure 
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4A). In conclusion replacing TGF-E3 with 20 % or 50 % PL has enhanced chondrogenic 
induction, while PL alone was sufficient to act as a chondrogenic inducer.  
In osteogenesis, replacing FCS with PL in the complete osteogenic media significantly 
enhanced Ca++ deposition in PL-MSCs (by 135 %) and FCS-MSCs (by 96 %), (p൑0.0002, 
Figure 4B). Although, the replacement of FCS with PL in the complete osteogenic media 
enhanced Ca++ deposition, PL-MSCs showed less potential for osteogenesis compared to FCS-
MSCs with Osteo–PL media (p<0.01, Figure 4B). Similarly, replacing FCS with PL in 
adipogenic media significantly increased the adipogenic induction by 40 % for PL-MSCs and 
30 % for FCS-MSCs compared to the complete adipogenic media (p<0.005, Figure 4C).  
PL maintains SF-MSCs immunomodulatory function 
In order to assess whether the immunomodulatory function of SF-MSCs is maintained in the 
presence of PL, PL-MSCs and FCS-MSCs were co-cultured with activated PBMCs for 5 days 
(Figure 5A). Clusters of lymphocytes in stimulated cultures lacking SF-MSCs were clearly 
visible, indicating lymphocyte proliferation (Figure 5B). However, in co-cultures with PL-
MSCs or FCS-MSCs, stimulated lymphocytes did not cluster, indicating the 
immunomodulatory effects of the SF-MSCs (Figure 5B). The proliferation index of viable 
CD14-CD4+CFSE+ cells significantly decreased with increases in PL-MSCs or FCS-MSCs 
numbers (p<0.0001 for both co-cultures, N=3, Figure 5C-D). This indicated that SF-MSCs had 
the capacity to inhibit the CD4+ T cells proliferation in a dose-dependent manner and that PL-
MSCs maintained this immunosuppression capacity at all ratios. No significant difference in 
the inhibition of CD4+ T cells proliferation between either FCS-MSCs or PL-MSCs was 
observed (Figure 5D).  
Other studies have reported the immunosuppression capacity of the BM-MSCs and AT-MSC 
which is comparable to SF-MSCs, as 1:10 ratio of T-cells: MSCs was capable of suppressing 
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stimulated T-cells proliferation and PL did not alter immunosuppression capacity of the BM-
MSCs [32] and AT-MSC cells [33].  
 
Discussion: 
Although it was historically thought that cartilage repair was the remit of BM-MSCs, there is 
increasing evidence from animal models for a pivotal or even dominant role for joint cavity 
MSCs including synovial fluid MSCs in cartilage repair [17, 18, 34, 35]. While there is a large 
amount of literature on the effect of PL on BM-MSCs, to the best of our knowledge this is the 
first study to investigate the effect of PL on SF-MSCs which are joint resident MSCs that have 
direct access to injured superficial cartilage. In this study, low number SF-MSCs were obtained 
from joint cavity and culture expanded before effects were studied. Given that SF-MSCs are 
likely to derive from synovium where native MSCs appear to be abundant in vivo[35],it is 
possible that the endogenous immunomodulatory activity within the joint is actually quite high. 
Our ex vivo findings indicate that PL has multiple effects on SF-MSCs including beneficial 
effects on their proliferation and chondrogenesis. These findings provide biological support for 
the concept that intra articular PL may have the potential to augment cartilage regeneration. 
Our findings of SF-MSCs immunomodulatory activity raise the possibility that allogenic SF-
MSCs could be used in conjunction with PL for therapy development.  These findings provide 
the impetus for further in vivo clinical research to optimally define the use of this strategy.   
Since SF-MSCs have the advantage of direct access to the site of injury without the need to 
breach the subchondral plate [36], combining PL with SF-MSCs might be relevant for early 
cartilage repair. Our results showed that PL maintained the in vitro phenotype in agreement 
with the recommendation of the ISCT [37]. Moreover, PL shortened SF-MSCs doubling times 
and increased SF-MSCs proliferation as they displayed bigger colony sizes. Similar 
observations have been reported in several studies with other types of MSCs, which promoted 
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PL as the gold standard for cell proliferation [22, 38]. There is data to show that activated 
platelet rich plasma PRP injected into subchondral bone with full thickness cartilage defects 
can profoundly affect SF-MSC numbers [39]. 
The trilineage differentiation potential of SF-MSCs expanded in PL revealed that PL 
preconditioned SF-MSCs towards chondrogenesis compared to FCS-MSCs. The PL expansion 
of MSCs according to their sources (bone marrow or synovial derived) influencing ex vivo 
differentiation is intriguing.  It has been shown that BM-MSCs expanded in PL have a greater 
capacity towards osteogenesis, while adipose-derived MSCs have more potential towards 
adipogenesis [24, 40, 41]. In this current work, we showed for the first time that PL favorably 
influenced SF-MSCs chondrogenesis (Figure 4). Taking these findings together, PL might 
modulate BM-MSCs towards osteogenesis and SF-MSCs towards chondrogenesis, with the 
latter capability being a potentially advantageous for intra-articular MSC manipulation, 
especially if PL were also to suppress SF-MSCs osteogenesis in the repair of partial thickness 
cartilage defects.  A proposed mechanism of PL priming BM-MSCs toward osteogenesis 
suggests elevation of osteoblastic genes expression alkaline phosphatase (ALP) and 
osteopontin (OP), as ALP and OP expression were significantly high compared to FCS 
expanded cells [24] and future study is warranted to investigate the molecular mechanisms of 
chondrogenic induction by PL in SF-MSCs. 
There is an interest in the use of third party “off the shelf” allogeneic MSCs for convenient 
intra articular injection or in combination with scaffolds for one stage cartilage repair strategies.  
In this work, we demonstrated for the first time that SF-MSCs has immunosuppression capacity 
which could support use of third party allogeneic SF-MSCs in addition to their enhanced 
chondrogenic differentiation capacity. A similar observation was reported for BM-MSCs and 
AT-MSC expanded in PL [32, 33, 42].  However, two previous studies have reported that PL 
expansion might in fact reduce MSCs immune suppression capability [43, 44], yet in these 
  
15 
studies different methods of PL preparation were used, compared to the PL used in this study. 
Copland et al. suggested this suppression of MSCs immunomodulation was due to the presence 
of fibrinogen, since a direct interaction between MSCs and fibrinogen lead to increased levels 
of IL-6, IL-8 and MCP-1 protein production and reduced the MSCs ability to up-regulate 
indoleamine dioxygenase (IDO) [43]. Although other studies have used fibrinogen rich PL, 
pooled from group O-typed and AB plasma donors, which showed that PL maintained 
immunomodulation of MSCs [20, 45]. Therefore, the presence of fibrinogen and ABO blood 
donor pooling might impact PL immunomodulation capacity. In this study, we used fibrinogen-
depleted PL in our cultures; which may explain our observations that PL had no detrimental 
effect of SF-MSCs ability to suppress CD4+ T cells proliferation. This could indicate that the 
introduction of PL in the joint cavity unlikely to alter the SF-MSCs capacity for 
immunosuppression. Further studies are required to investigate the impact of fibrinogen in PL 
on SF-MSCs immunomodulation. 
 
TGF-E is an important factor for cartilage maintenance in vivo and it is a major inducer of 
chondrogenesis in vitro [46]. Moreover, TGF-Ereduces activity of IL-E1, degradation of type 
II collagen, and proteoglycan in OA [47]. Complete chondrogenic media is composed of 
several inducers combined with TGF-E and it was shown that the combination of TGF-E and 
IGF-I enhances chondrogenic differentiation [48, 49]. To the best of our knowledge, our 
strategy of incremental TGF-E substitution with PL and looking at ensuing degrees of in vitro 
chondrogenesis is novel since there was no data on PL as chondrogenic inducer and as 
replacement of TGF-E in complete chondrogenic media. There is also only limited data of the 
use of PRP concentrate (as a gel) with complete chondrogenic media, consistent with our study 
it showed enhanced chondrogenesis [50]. The results presented here showed that PL has a 
potential to act as chondrogenic inducer, as chondrogenic media containing 20 % PL was 
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sufficient to replace 10 ng TGF-E and induce chondrogenesis. The amount of TGF-E in 100 % 
PL (Stemulate) is approximately 75 ng, according to the manufacturer, in this study we use 20 
% PL which contains approximately 14.4 ng TGF-Eto successfully induce chondrogenesis of 
SF-MSCs. As the increase of sGAG production with 20 % PL was more than 69 % compared 
to complete chondrogenic media, this suggests there are other inducers in PL which aided in 
the chondrogenic enhancement. Interestingly, our findings showed that PL alone can also 
induce chondrogenesis similar to complete chondrogenic media as indicated by sGAG 
production.  
On the other hand, in osteogenesis replacing FCS with PL enhanced Ca++ deposition for both 
PL-MSCs and FCS-MSCs. However, PL-MSCs showed less Ca++ deposition compared FCS-
MSCs which collectively supports that PL-MSCs are per-conditioned toward chondrogenesis.  
Taking the above findings our data supports the concept of using PL and SF-MSCs as tool for 
cartilage repair.  
 
In summary, PL has the potential to promote SF-MSCs proliferation, maintain 
immunophenotype and immunosuppression, and pre-conditions SF-MSCs towards 
chondrogenesis. These findings suggest that PL introduced into the joint cavity could influence 
local, resident MSCs and that this might be relevant for OA therapy development.  Our findings 
provide a basis toward the further exploration of PL and SF-MSCs therapy cellular therapy for 
early OA. 
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Figure Legends 
Figure 1. Immunophenotype of cultured FCS-MSC and PL-MSC analyzed by flow cytometry. 
Isotype control (dark histograms) and cells stained with antibody against the surface proteins 
(light histogram). The results presented are Mean percentage expression ± SD, N=3 donors-
matched. 
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Figure 2. SF-MSCs proliferation. (A) A representative CFU-F plate seeded in FCS media and 
single colony under 100x magnification. (B) CFU-F plate seeded in PL media and single 
colony under 100x magnification. (C) Average colony diameter in mm. (D) Cultured SF-MSCs 
doubling time at p0. (E) Average colony numbers in CFU-F/ml. (F) Impact of PL on SF-MSCs 
adhesion; cells were divided into 2 groups: FCS (48h): cells seeded in FCS media for 48 hours 
before exchanging to 5% PL media for the next 12 days. PL (48h): cells seeded with 5 % PL 
media for 48 hours before exchanging to FCS media for the next 12 days. Wilcoxon matched-
pairs test, *p<0.01, N=7 donor-matched samples. 
 
Figure 3. SF-MSCs expanded with PL have greater chondrogenic capacity (A) PL-MSCs and 
FCS-MSCs pellets after 21 days culture in complete chondrogenic media, scale bar represents 
1 mm. Insert, stained section of the chondrogenic pellet with 1 % toluidine blue and sGAG 
production from donor matched cultures. (B) Alizarin Red staining of PL-MSCs and FCS-
MSCs after 21 days culture in complete osteogenic media and Ca++ deposition from donor 
matched cultures. (C) Oil Red staining of PL-MSCs and FCS-MSCs after 21 days culture in 
complete adipogenic media (complete Adipo) and lipid production quantification using the 
Nile Red/DAPI fluorescent ratio. Wilcoxon matched-pairs test, *p<0.05, N=5 donors. 
 
Figure 4. PL as trilineage differentiation inducer. (A) sGAG production of PL-MSCs and FCS-
MSCs with different chondrogenic media: Complete chondro: complete chondrogenic media; 
basal-20 % PL: basal chondrogenic media supplemented with 20 % PL; basal-50 % PL: basal 
chondrogenic media supplemented with 50 % PL; DMEM-50 % PL: high glucose DMEM with 
50 % PL only, control; DMEM high glucose with 20 % FCS only. (B) Ca++ deposition of PL-
MSCs and FCS-MSCs with complete osteogenic media and PL-Osteo: osteogenic media with 
10 % PL instead of FCS.  (C) Nile Red/DAPI fluorescent ratio of PL-MSCs and FCS-MSCs 
with complete adipogenic media (complete Adipo) and PL-Adipo: Adipogenic media used 10 
% PL instead of FCS, two-way ANOVA–Bonferroni's multiple comparisons test, 
****p<0.0001, ***p<0.0005, **p<0.005, *P<0.01, N=5 donors. 
 
Figure 5. Immunomodulation of PL-MSCs and FCS-MSCs. PMBCs co-cultured for 5 days 
with either with FCS- MSCs or PL-MSCs at the following ratios 1:1, 2:1, 5:1, and 10:1, 
Stimulated (positive control): PMBCs with no SF-MSCs. CD3/CD28 beads were added to all 
wells except non-stimulated (negative control) 1:0. (A) illustration of immunomodulation 
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experiment steps. (B) Representative light microscopic image at day 5. (C) Representative 
Modfit graphs showing CD4+ T cells populations, blue peak represents parent population with 
subsequent generations represented in multiple colour. (D) Proliferation index of T-
lymphocyte. n=3, two-way ANOVA, Bonferroni post t test, ****p<0.0001, N=3 donors. 
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